Eli Lilly stock extends gains as obesity and diabetes drugs drive revenue growth

Eli Lilly & Co. (ISIN US5324571083) has seen Eli Lilly stock benefit from strong demand for its new-generation obesity and diabetes medicines, with the company reporting that total revenue rose to about $34.1 billion in fiscal 2023, up roughly one fifth from the prior year, according to its latest annual report.

Revenue up around 20 percent in 2023

According to the companys 2023 annual reporting, Eli Lilly generated approximately $34.1 billion in revenue for fiscal 2023, compared with roughly $28.5 billion in 2022, implying year on year growth of about 20 percent as new products scaled and older franchises held up.

Within that headline figure, the group highlighted that newer therapies in diabetes and obesity contributed a growing share of sales, while legacy products such as insulin categories and immunology treatments continued to provide a substantial revenue base across global markets.

Operating performance and earnings momentum

The same annual filing indicated that Eli Lillys reported net income for 2023 was in the region of $5.2 billion, up from roughly $2.2 billion in 2022, reflecting both higher sales and improved operating leverage as manufacturing volumes increased.

On a per-share basis, the company outlined that its earnings per share for 2023 more than doubled versus the prior year, illustrating how incremental revenue from obesity and diabetes medicines flowed through to the bottom line once initial launch expenses and production ramp-up costs were absorbed.

Obesity and diabetes franchise expansion

Eli Lilly has emphasized in its communications that its obesity and diabetes portfolio, including its incretin-based therapies, generated multibillion dollar revenue in 2023, helping to drive the companys double-digit top-line growth compared with 2022.

The company has also pointed to robust prescription trends and ongoing launches in new geographies as a driver of further volume growth in 2024, while noting that it is investing heavily in manufacturing capacity to support rising demand and reduce supply constraints for these drugs.

Cash flow, investment, and balance sheet

In its 2023 financial disclosures, Eli Lilly reported strong operating cash flow that supported both capital expenditure for new production facilities and shareholder returns via dividends, with the company indicating that it returned several billion dollars to shareholders in the form of dividends over the course of the year.

Management also highlighted that research and development spending reached into the double-digit billions of dollars in 2023, underlining the groups commitment to advancing its pipeline in obesity, diabetes, oncology, and neuroscience, even as current blockbuster products contribute a rising share of earnings.

Flagship incretin therapy for weight management

One of the companys flagship products is an incretin-based injectable therapy used for chronic weight management in adults with obesity or overweight accompanied by weight-related conditions, which has quickly become a key pillar of Eli Lillys growth strategy.

Eli Lilly has stated that demand for this therapy has outpaced initial expectations in several markets, prompting the company to invest in additional manufacturing lines and supply-chain capacity to minimize shortages and better match prescription volumes.

Eli Lilly stock on the NYSE

Eli Lilly stock is listed on the New York Stock Exchange under the ticker LLY, and the company is a constituent of major US equity benchmarks, including the S&P 500 index, which makes the shares a widely held large-cap healthcare name among institutional and retail investors.

With a market capitalization that has risen to well over $500 billion in recent periods, Eli Lilly ranks among the most valuable global pharmaceutical companies, reflecting investors expectations that its obesity and diabetes franchises will generate substantial cash flows over a multi-year horizon.